Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


September D-Day for 3rd-gen contraceptives

This article was originally published in Scrip

Executive Summary

The European Medicines Agency says it has widened the scope of its safety review of third-generation contraceptives and is gathering information from a range of sources including new EU drug utilisation studies. A conclusion on the products' benefit-risk profile is expected by September, Noël Wathion, the agency's head of patient health protection, told a meeting of the European Parliament's environment and public health committee (ENVI) on 26 March.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts